Standard Biotools Stock Debt To Equity
| LAB Stock | USD 1.82 0.11 6.43% |
Standard Biotools fundamentals help investors to digest information that contributes to Standard Biotools' financial success or failures. It also enables traders to predict the movement of Standard Stock. The fundamental analysis module provides a way to measure Standard Biotools' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Standard Biotools stock.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | 0.42 | 0.80 |
Standard | Debt To Equity |
Standard Biotools Company Debt To Equity Analysis
Standard Biotools' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Standard Biotools Debt To Equity | 0.38 % |
Most of Standard Biotools' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Standard Biotools is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Standard Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Standard Biotools is extremely important. It helps to project a fair market value of Standard Stock properly, considering its historical fundamentals such as Debt To Equity. Since Standard Biotools' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Standard Biotools' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Standard Biotools' interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
Standard Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, Standard Biotools has a Debt To Equity of 0.378%. This is 99.29% lower than that of the Life Sciences Tools & Services sector and 99.51% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.22% higher than that of the company.
Standard Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Standard Biotools' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Standard Biotools could also be used in its relative valuation, which is a method of valuing Standard Biotools by comparing valuation metrics of similar companies.Standard Biotools is currently under evaluation in debt to equity category among its peers.
Standard Fundamentals
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.80) % | ||||
| Operating Margin | (0.29) % | ||||
| Current Valuation | 359.71 M | ||||
| Shares Outstanding | 372.26 M | ||||
| Shares Owned By Insiders | 1.93 % | ||||
| Shares Owned By Institutions | 73.30 % | ||||
| Number Of Shares Shorted | 19.54 M | ||||
| Price To Earning | (2.52) X | ||||
| Price To Book | 1.30 X | ||||
| Price To Sales | 4.08 X | ||||
| Revenue | 106.34 M | ||||
| Gross Profit | (1.45 M) | ||||
| EBITDA | (54.46 M) | ||||
| Net Income | (74.66 M) | ||||
| Cash And Equivalents | 81.31 M | ||||
| Cash Per Share | 2.68 X | ||||
| Total Debt | 98.21 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 5.87 X | ||||
| Book Value Per Share | 1.23 X | ||||
| Cash Flow From Operations | (43.29 M) | ||||
| Short Ratio | 6.50 X | ||||
| Earnings Per Share | (0.69) X | ||||
| Price To Earnings To Growth | 0.31 X | ||||
| Target Price | 3.08 | ||||
| Number Of Employees | 534 | ||||
| Beta | 1.57 | ||||
| Market Capitalization | 636.56 M | ||||
| Total Asset | 323.07 M | ||||
| Retained Earnings | (1 B) | ||||
| Working Capital | 48.89 M | ||||
| Net Asset | 323.07 M |
About Standard Biotools Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Standard Biotools's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Standard Biotools using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Standard Biotools based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Standard Biotools offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Standard Biotools' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Standard Biotools Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Standard Biotools Stock:Check out Standard Biotools Piotroski F Score and Standard Biotools Altman Z Score analysis. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. If investors know Standard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Standard Biotools listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.558 | Quarterly Revenue Growth (0.14) | Return On Assets (0.15) | Return On Equity (0.37) |
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Standard Biotools' value and its price as these two are different measures arrived at by different means. Investors typically determine if Standard Biotools is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Standard Biotools' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.